Pichala Priyanka Tejashwani, Kumar Bharani Mukkillapati, Zachariah Seeba, Thomas Dixon, Saunchez Laura, Gerardo Alvarez-Uria
Department of Pharmacy Practice, Raghavendra Institute of Pharmaceutical Education and Research, Andhra Pradesh, India.
Intensive Care Unit, Rural Development Trust Hospital, Andhra Pradesh, India.
J Basic Clin Pharm. 2013 Jun;4(3):64-7. doi: 10.4103/0976-0105.118801.
Intensive care unit is a potential area for drug-related problems. As many of the patients treated are complex patients, clinical pharmacy intervention could find drug therapy problems.
Drug information liaisons daily attended ward rounds with intensivists and screened the patient for drug therapy assessment using the American Society for Health-System Pharmacists clinical skills competition DTA format. This was a prospective study done for 6 months from August 2012 to January 2013. Simple statistics were used to tabulate the drug-related problems assessed.
A total of 72 patients were screened for drug therapy problems, for which 947 drug doses were prescribed in the study period. The total number of prescriptions was 148. The average number of drugs per prescription was 6.39 and the average number of drugs per patient was 13.15. A total of 243 problems were identified; on an average, 1.67 problems were present per prescription. The total number of drug interactions identified was N = 192 (78.2%); majority of them (61.4%) were of type C (not serious). So, 55.73% of them were monitored and not stopped or substituted. The second type of problem was a correlation between drug therapy and medical problem (7.4%). Appropriate drug selection and drug regimen was the third problem, and the adverse drug reactions and therapeutic duplications accounted for approximately 2% of the drug-related problems identified.
Drug interactions constituted the major problem of ICUs, but not many were serious or significant. Consensus in assessment of drug-related problems and convincing intensivists with good quality evidences are required for better acceptance of interventions.
重症监护病房是药物相关问题的潜在高发领域。由于许多接受治疗的患者病情复杂,临床药学干预有助于发现药物治疗问题。
药物信息联络员每天与重症监护医生一起查房,并使用美国卫生系统药师协会临床技能竞赛的药物治疗评估(DTA)格式对患者进行药物治疗评估筛查。这是一项从2012年8月至2013年1月为期6个月的前瞻性研究。使用简单统计学方法将评估出的药物相关问题制成表格。
共对72例患者进行了药物治疗问题筛查,研究期间共开出947剂药物。处方总数为148张。每张处方的平均药物数量为6.39种,每位患者的平均药物数量为13.15种。共识别出243个问题;平均每张处方存在1.67个问题。识别出的药物相互作用总数为N = 192(78.2%);其中大多数(61.4%)为C类(不严重)。因此,其中55.73%的药物相互作用进行了监测,未停药或换药。第二类问题是药物治疗与医疗问题之间的相关性(7.4%)。药物选择和用药方案合理是第三个问题,药物不良反应和治疗重复约占已识别出的药物相关问题的2%。
药物相互作用是重症监护病房的主要问题,但严重或显著的并不多。为了更好地接受干预措施,需要在药物相关问题评估上达成共识,并以高质量证据说服重症监护医生。